MA5-13498

antibody from Invitrogen Antibodies

Targeting: CDK4 PSK-J3

Provider product page for MA5-13498

Western blot

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [21]
Comments [0]
Validations
Western blot [2]
Flow cytometry [2]
Other assay [1]

Submit

Product number: MA5-13498 - Provider product page
Provider: Invitrogen Antibodies
Product name: Cdk4 Monoclonal Antibody (DCS-31)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MA5-13498 targets Cdk4 in IF, IP, FACS and WB applications and shows reactivity with Human, mouse, and Rat samples.
Antibody clone number: DCS-31
Concentration: 0.2 mg/mL

CDK4 protein structure - MA5-13498 shown in red.

Submitted references Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Saâda-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D, Birtwisle-Peyrottes I, Chetaille B, Bouvier C, Château MC, Peoc'h M, Battistella M, Bazin A, Gal J, Michiels JF, Coindre JM, Pedeutour F, Bianchini L
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015 Nov;28(11):1404-14

Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report.

Weingertner N, Neuville A, Chibon F, Ray-Coquard I, Marcellin L, Ghnassia JP
Applied immunohistochemistry & molecular morphology : AIMM 2015 Mar;23(3):230-5

Plexiform fibromyxoma (plexiform angiomyxoid myofibroblastic tumor) of stomach: an unusual presentation as a fistulating abscess.

Lee PW, Yau DT, Lau PP, Chan JK
International journal of surgical pathology 2014 May;22(3):286-90

Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases.

Sioletic S, Dal Cin P, Fletcher CD, Hornick JL
Histopathology 2013 Jan;62(2):287-93

The APC/C activator Cdh1 regulates the G2/M transition during differentiation of placental trophoblast stem cells.

Naoe H, Chiyoda T, Ishizawa J, Masuda K, Saya H, Kuninaka S
Biochemical and biophysical research communications 2013 Jan 11;430(2):757-62

Incidental lipoma-like hibernoma arising from the adrenal gland: a well-differentiated liposarcoma mimicker.

Val-Bernal JF, Azueta A, Ortiz-Rivas LA, Fuentes J, Ballestero R
Pathology, research and practice 2013 Dec;209(12):812-6

Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor.

Kashima T, Halai D, Ye H, Hing SN, Delaney D, Pollock R, O'Donnell P, Tirabosco R, Flanagan AM
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 Oct;25(10):1384-96

MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.

Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, Shibata T
The American journal of surgical pathology 2012 Mar;36(3):423-31

MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.

Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret Ad, Louis-Brennetot C, Aurias A, Coindre JM, Guillou L, Pedeutour F, Duval H, Collin C, de Pinieux G
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2011 May;24(5):624-37

Malignant fat-forming solitary fibrous tumor (so-called "lipomatous hemangiopericytoma"): clinicopathologic analysis of 14 cases.

Lee JC, Fletcher CD
The American journal of surgical pathology 2011 Aug;35(8):1177-85

Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.

Rocha AS, Paternot S, Coulonval K, Dumont JE, Soares P, Roger PP
Molecular biology of the cell 2008 Nov;19(11):4814-25

Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity.

James MK, Ray A, Leznova D, Blain SW
Molecular and cellular biology 2008 Jan;28(1):498-510

The LxCxE pRb interaction domain of cyclin D1 is dispensable for murine development.

Landis MW, Brown NE, Baker GL, Shifrin A, Das M, Geng Y, Sicinski P, Hinds PW
Cancer research 2007 Aug 15;67(16):7613-20

Requirement for CDK4 kinase function in breast cancer.

Yu Q, Sicinska E, Geng Y, Ahnström M, Zagozdzon A, Kong Y, Gardner H, Kiyokawa H, Harris LN, Stål O, Sicinski P
Cancer cell 2006 Jan;9(1):23-32

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Jul 1;11(13):4875-87

p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2.

Rodier G, Makris C, Coulombe P, Scime A, Nakayama K, Nakayama KI, Meloche S
The Journal of cell biology 2005 Jan 3;168(1):55-66

Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.

Coindre JM, Hostein I, Maire G, Derré J, Guillou L, Leroux A, Ghnassia JP, Collin F, Pedeutour F, Aurias A
The Journal of pathology 2004 Jul;203(3):822-30

Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.

Coindre JM, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre-Guillevin E, Bui NB, Stoeckle E, Hostein I, Aurias A
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2003 Mar;16(3):256-62

Regulation and role of p21 and p27 cyclin-dependent kinase inhibitors during hepatocyte differentiation and growth.

Ilyin GP, Glaise D, Gilot D, Baffet G, Guguen-Guillouzo C
American journal of physiology. Gastrointestinal and liver physiology 2003 Jul;285(1):G115-27

Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII.

Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA
The Journal of biological chemistry 2003 Feb 14;278(7):5292-9

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.

Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H
Molecular and cellular biology 1999 Oct;19(10):7011-9

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of CDK4 was performed with 10 µg of HeLa cells transfected with Transfection Reagent alone (Lane 1), 100nM Non-Targeting control siRNA (Lane 2), or 100nM siRNA against CDK4 (Lane 3). Proteins were resolved using a NuPAGE® Novex 4-12% Bis-Tris Gel (Product # NP0322BOX), XCell SureLock™ Electrophoresis System (Product # EI0002), and a protein size ladder. Proteins were wet transferred to a Pierce Nitrocellulose Membrane (Product # 88025) OR Pierce PVDF Membrane (Product # 88518) and blocked with Pierce Starting Block T20 (PBS) Blocking Buffer (Product # 37539) for 1 hour at room temperature. CDK4 was detected at ~ 30 kDa using CDK4 Mouse monoclonal antibody (Product # MA5-13498) diluted in Pierce Starting Block T20 (PBS) Blocking Buffer 4°C overnight on a rocking platform. Pierce Goat Anti-Mouse (Product # 31437) HRP-Conjugated Antibodies at a 1:2500 dilution were used and chemiluminescent detection was performed using Pierce Supersignal West Dura Maximum Sensitivity Substrate (Product # 37071). Relative density of the bands normalized to Cyclophilin B (21 kDa). CDK4 Antibody (Product # MA5-13498) confirms silencing of CDK4 expression.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot of Cdk4 using Cdk4 Monoclonal Antibody (MA5-13498) on LS174T Cells, MAD109 Cells and CCL-4 med Cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of Cdk4 in C6 cells compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/ml, fixed with 2% paraformaldehyde and washed with PBS. Cells were penetrated by dropping the supernatant, adding 90% methanol and incubated for 10 minutes at room temperature. Follwing penetration, cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a Cdk4 monoclonal antibody (Product # MA5-13498) at a dilution of 0.5 ug/test for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated goat anti-mouse IgG (H+L) secondary antibody and re-suspended in PBS for FACS analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of Cdk4 in MCF-7 cells compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/ml, fixed with 2% paraformaldehyde and washed with PBS. Cells were penetrated by dropping the supernatant, adding 90% methanol and incubated for 10 minutes at room temperature. Follwing penetration, cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a Cdk4 monoclonal antibody (Product # MA5-13498) at a dilution of 0.5 ug/test for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated goat anti-mouse IgG (H+L) secondary antibody and re-suspended in PBS for FACS analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of Cdk4 using Cdk4 Monoclonal Antibody (MA5-13498) on Native Mouse MAD109 Cells.